Entering text into the input field will update the search result below

Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q2 2020 Results - Earnings Call Transcript

May 07, 2020 10:08 PM ETAnavex Life Sciences Corp. (AVXL)2 Comments
SA Transcripts profile picture
SA Transcripts

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2020 Earnings Conference Call May 7, 2020 4:30 PM ET

Company Participants

Clint Tomlinson – Investor Relations

Christopher Missling – President and Chief Executive Officer

Sandra Boenisch – Principal Financial Officer

Conference Call Participants

Raghuram Selvaraju – H.C. Wainwright

Tom Bishop – BI Research


Good afternoon. My name is Adriane, and I will be your conference call operator today. Welcome to the Anavex Life Sciences Fiscal 2020 Second Quarter Financial Results Conference Call. As a reminder, this conference call is being recorded.

I’d now like to turn the call over to your host for today's conference, Clint Tomlinson. Please go ahead.

Clint Tomlinson

Thank you and good afternoon, everyone. We appreciate you joining us today for Anavex Life Sciences' conference call and webcast. Our agenda is to review the company's financial results for its second quarter of fiscal 2020 and provide a clinical study update. A taped replay of this call will be available approximately two hours after the call's conclusion and will remain available for one month. The call will also be available for replay on Anavex's website at www.anavex.com.

With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer. Dr. Missling and Ms. Boenisch will make prepared remarks, and then we will take questions from equity analysts.

Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the SEC. This includes, without limitation, the company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in those forward-looking statements.

These factors may include, without limitation, risks inherent in the development of – and/or commercialization

Recommended For You

Comments (2)

Anavex is amazing. Anavex 2-73 and Anavex 3-71 both are agonists for the sigma 1 receptor and the muscarinic receptors

Look at the information at the following links:




Good luck and GOD bless,
Lion66 profile picture
You think it works?
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.